Advocacy Priorities for NCPO Organizations 2015
Similarity in our Interests

- Enhancing the regulatory environment
- Part D/MTM Program
- Provider status for pharmacists
- Controlled substances abuse prevention
- Pharmacy compounding
- Patient access to medicines and pharmacists’ services
American Association of Colleges of Pharmacy (AACP)

- Funding for public health/research agencies
- Funding for higher education and health professions education (including reauthorization of the HEA)
- Issues which advance practice ability of pharmacy graduates and licensees (including Medicare provider status)
Access and coverage for consumers to pharmacists’ services ("Provider Status")
  * Federal
  * Private payers
  * State
* Medicare Part D MTM program improvements
* Pharmacy compounding
* Prescription drug abuse
* Preferred pharmacy networks
American Society of Health-System Pharmacists (ASHP)

- Pass federal legislation to amend the Social Security Act to recognize pharmacists as Medicare Part B providers in medically underserved areas
- Work with states to ensure that patients have sufficient access to the patient care services of pharmacists
- Help ensure successful implementation of Title 1 (Drug Compounding) and Title 2 (Drug Supply Chain Security) of the Drug Quality and Security Act
- Work with FDA and other stakeholders to help prevent and minimize the impact of drug shortages
Biotechnology Industry Organization (BIO)

* Advocate for a shared national research commitment through a large-scale longitudinal study related to Alzheimer’s and other chronic conditions
* Promote a science-based FDA regulatory environment that supports biomedical innovation, including the development, use and regulatory adoption of modern research tools and approaches to clinical R&D programs
* Demonstrate the promise of value and innovation, and work to ensure timely access to innovative therapies for patients
* Ensure biosimilars policy protects safety and promotes biomedical innovation
* Encourage the continued growth of biotech innovators at all stages of the development process, from early-stage small businesses to multinational corporations
Preventing new take-back mandates, and pursuing industry consensus on alternatives to existing mandates

Restoration of OTC eligibility in tax preferred accounts such as FSAs and HSAs

Preventing undue limits on the availability of nonprescription medicines with pseudophedrine (or other ingredients)

Enhancing FDA performance by modernizing the OTC monograph system and enhancing Rx-OTC switch
Healthcare Distribution Management Association (HDMA)

- Ongoing implementation of Drug Supply Chain Security Act (DSCSA)
- Reintroduction of legislation (H.R. 4709/S. 2862) to clarify certain provisions of the Controlled Substances Act
- Corporate tax reform
- State legislative and regulatory issues pertaining state licensure, drug abuse and disposal
Abuse and diversion of controlled substances
- Continue efforts to provide state boards of pharmacy, pharmacists, practitioners, and stakeholders with the information and assistance needed to combat the abuse of controlled substances epidemic

Uniform inspection blueprint
- Complete the acceptance of a uniform blueprint by the states for the general inspection of pharmacies and focused practices such as sterile and non-sterile compounding

Dot Pharmacy
- Execute the launch of dot pharmacy top level domain (TLD) to distinguish legitimate pharmacies and websites and subsequently establish the dot pharmacy community globally
National Association of Chain Drug Stores (NACDS)

- Pharmacy Care
- Medicare Provider Status
- Part D MTM Single Chronic Condition
- State Scope of Practice
- Implementation of AMP-Based FULs
National Community Pharmacists Association (NCPA)

* Passing state and federal MAC bills to address the delay in generic prescription product payment rate updates
* Any willing pharmacy having access to Medicare Part D preferred networks
* Regulatory advocacy on new definitions of how Medicaid calculates its payments to pharmacies (e.g. NADAC)
* Pharmacist provider status
Ensuring patient access and affordability for therapies in the implementation of the ACA federal and state exchanges

Maintaining and enhancing access to innovative therapies in the Medicare Part D program

Ensuring that the 340B program covers the patients for which it was originally intended

Enactment of the 21st Century Cures legislation that enhances the regulatory process and its ability to expeditiously review new medicines
Common Priorities

- Enhancing the regulatory environment
- Part D/MTM Program
- Provider status for pharmacists
- Controlled substances abuse prevention
- Pharmacy compounding
- Patient access to medicines and pharmacists’ services